Thomas Burrow
Credentials | Fellow, American Academy of Pediatrics |
---|
| Fellow, American Board of Medical Genetics and Genomics, Clinical Genetics |
---|
| Fellow, American Board of Medical Genetics and Genomics, Medical Biochemical Genetics |
---|
Title | Assistant Professor |
---|
Institution | University of Arkansas for Medical Sciences |
---|
Department | Peds Pediatrics, College of Medicine |
---|
Division | Peds Genetics |
---|
Address | 1900 Maryland Street Mail Slot # 512-22 Little Rock AR 72202
|
---|
Phone | 501-364-2966 |
---|
vCard | Download vCard |
---|
|
|
|
Affiliation American Academy of Pediatrics Alpha Omega Alpha American College of Medical Genetics American Society of Human Genetics Society of Inherited Metabolic Diseases
Biography Research ATB200-07 (BURROW, THOMAS A)Mar 6, 2020 - Mar 5, 2030 Amicus Therapeutics No FP attached Role: Principal Investigator |
| ATB200 (BURROW, THOMAS)Aug 10, 2019 Amicus Therapeutics A PHASE 3 DOUBLE-BLIND RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE-ONSET POMPE DISEASE COMPARED WITH ALGLUCOSIDASE ALFA/PLACEBO (IRB 228872) Role: Principal Investigator |
| ATB200-03 (BURROW, THOMAS A)Aug 10, 2019 Amicus Therapeutics No FP attached Role: Principal Investigator |
| PB (BURROW, THOMAS)Oct 30, 2018 Protalix Ltd A Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated With Agalsidase Beta Role: Principal Investigator |
| PB-102-F20 (BURROW, THOMAS A)Oct 30, 2018 Protalix Ltd No FP attached Role: Principal Investigator |
| VTS-270-001 (BURROW, THOMAS A)Aug 29, 2018 - Aug 28, 2028 Mallinckrodt Pharmaceuticals No FP attached Role: Principal Investigator |
| VTS (BURROW, THOMAS)Aug 29, 2018 Mallinckrodt Pharmaceuticals An Open-label Expanded Access Treatment Protocol for VTS-270 (2-hydroxypropyl-ß-cyclodextrin) in Patients with Neurologic Manifestations of Niemann-Pick Type C Disease (NPC) Role: Principal Investigator |
| DIREGC07006 (BURROW, THOMAS A)Mar 12, 2018 - Mar 18, 2028 Genzyme No FP attached Role: Principal Investigator |
Bibliographic The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System. 33. Mistry P, Balwani, M, Barbouth D, Burrow TA, Ginns EI, Goker-Alpan O, Grabowski, GA, Kartha RV, Kishnani PS, Lau H, Lee CU, Lopez G, Maegawa G, Packman S, Prada C, Rosenbloom B, Lal TR, Schiffmann R, Weinreb N, Sidransky E. Mol Genet Metab. 2020. 130(3):164-9. PMID: 32471800.32. Samanta D, Ramakrishnaiah R, Crary SE Burrow TA. Multiple Autoimmune Disorders in Aicardi-Goutieres Syndrome. Pediatr Neurol. 2019. 96:37-9. PMID: 30898416
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
Don't see publications published under other names? Login to add alternative names.
-
Samanta D, Veerapandiyan A, Burrow TA, Gokden M. Mitochondrial Ultrastructural Defects in NDUFS3-Related Disorder. J Pediatr Neurosci. 2021 Oct-Dec; 16(4):299-302. PMID: 36531773.
-
Grant N, Taylor JM, Plummer Z, Myers K, Burrow T, Luchtman-Jones L, Byars A, Hammill A, Wusick K, Smith E, Leach J, Vadivelu S. Case Report: Cerebral Revascularization in a Child With Mucopolysaccharidosis Type I. Front Pediatr. 2021; 9:606905. PMID: 34178879.
-
Abell K, Chadwell SE, Burrow TA, Becker APP, Bailey L, Steele P, Zhang X, Islas-Ohlmayer M, Bittencourt R, Schwartz IVD, Prada CE. Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States. Am J Med Genet C Semin Med Genet. 2020 12; 184(4):1052-1059. PMID: 33277783.
-
Samanta D, Ramakrishnaiah R, Crary SE, Sukumaran S, Burrow TA. Multiple Autoimmune Disorders in Aicardi-Gouti?res Syndrome. Pediatr Neurol. 2019 07; 96:37-39. PMID: 30898416.
-
Metz KA, Teng X, Coppens I, Lamb HM, Wagner BE, Rosenfeld JA, Chen X, Zhang Y, Kim HJ, Meadow ME, Wang TS, Haberlandt ED, Anderson GW, Leshinsky-Silver E, Bi W, Markello TC, Pratt M, Makhseed N, Garnica A, Danylchuk NR, Burrow TA, Jayakar P, McKnight D, Agadi S, Gbedawo H, Stanley C, Alber M, Prehl I, Peariso K, Ong MT, Mordekar SR, Parker MJ, Crooks D, Agrawal PB, Berry GT, Loddenkemper T, Yang Y, Maegawa GHB, Aouacheria A, Markle JG, Wohlschlegel JA, Hartman AL, Hardwick JM. KCTD7 deficiency defines a distinct neurodegenerative disorder with a conserved autophagy-lysosome defect. Ann Neurol. 2018 11; 84(5):766-780. PMID: 30295347.
-
Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Am J Hematol. 2017 Sep; 92(9):929-939. PMID: 28569047.
-
Pandey MK, Burrow TA, Rani R, Martin LJ, Witte D, Setchell KD, Mckay MA, Magnusen AF, Zhang W, Liou B, K?hl J, Grabowski GA. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature. 2017 03 02; 543(7643):108-112. PMID: 28225753.
-
Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Goker-Alpan O, Watman N, El-Beshlawy A, Kishnani PS, Pedroso ML, Gaemers SJM, Tayag R, Peterschmitt MJ. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. Blood. 2017 04 27; 129(17):2375-2383. PMID: 28167660.
-
Elstein D, Burrow TA, Charrow J, Giraldo P, Mehta A, Pastores GM, Lee HM, Mellgard B, Zimran A. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease. Mol Genet Metab. 2017 Jan - Feb; 120(1-2):111-115. PMID: 27614581.
-
Schuurs-Hoeijmakers JH, Landsverk ML, Foulds N, Kukolich MK, Gavrilova RH, Greville-Heygate S, Hanson-Kahn A, Bernstein JA, Glass J, Chitayat D, Burrow TA, Husami A, Collins K, Wusik K, van der Aa N, Kooy F, Brown KT, Gadzicki D, Kini U, Alvarez S, Fern?ndez-Ja?n A, McGehee F, Selby K, Tarailo-Graovac M, Van Allen M, van Karnebeek CD, Stavropoulos DJ, Marshall CR, Merico D, Gregor A, Zweier C, Hopkin RJ, Chu YW, Chung BH, de Vries BB, Devriendt K, Hurles ME, Brunner HG. Clinical delineation of the PACS1-related syndrome--Report on 19 patients. Am J Med Genet A. 2016 Mar; 170(3):670-5. PMID: 26842493.
-
Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, Kishnani PS, Mistry P, Ruskin J, Weinreb N. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab. 2016 Feb; 117(2):95-103. PMID: 26387627.
-
Valencia CA, Husami A, Holle J, Johnson JA, Qian Y, Mathur A, Wei C, Indugula SR, Zou F, Meng H, Wang L, Li X, Fisher R, Tan T, Hogart Begtrup A, Collins K, Wusik KA, Neilson D, Burrow T, Schorry E, Hopkin R, Keddache M, Harley JB, Kaufman KM, Zhang K. Clinical Impact and Cost-Effectiveness of Whole Exome Sequencing as a Diagnostic Tool: A Pediatric Center's Experience. Front Pediatr. 2015; 3:67. PMID: 26284228.
-
Lindsley AW, Saal HM, Burrow TA, Hopkin RJ, Shchelochkov O, Khandelwal P, Xie C, Bleesing J, Filipovich L, Risma K, Assa'ad AH, Roehrs PA, Bernstein JA. Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome. J Allergy Clin Immunol. 2016 Jan; 137(1):179-187.e10. PMID: 26194542.
-
Esmaeeli Nieh S, Madou MR, Sirajuddin M, Fregeau B, McKnight D, Lexa K, Strober J, Spaeth C, Hallinan BE, Smaoui N, Pappas JG, Burrow TA, McDonald MT, Latibashvili M, Leshinsky-Silver E, Lev D, Blumkin L, Vale RD, Barkovich AJ, Sherr EH. De novo mutations in KIF1A cause progressive encephalopathy and brain atrophy. Ann Clin Transl Neurol. 2015 Jun; 2(6):623-35. PMID: 26125038.
-
Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015 Jun 13; 385(9985):2355-62. PMID: 25819691.
-
Burrow TA, Sun Y, Prada CE, Bailey L, Zhang W, Brewer A, Wu SW, Setchell KDR, Witte D, Cohen MB, Grabowski GA. CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings. Mol Genet Metab. 2015 Feb; 114(2):233-241. PMID: 25219293.
-
Levinsohn JL, Teng J, Craiglow BG, Loring EC, Burrow TA, Mane SS, Overton JD, Lifton RP, McNiff JM, Lucky AW, Choate KA. Somatic HRAS p.G12S mutation causes woolly hair and epidermal nevi. J Invest Dermatol. 2014 Apr; 134(4):1149-1152. PMID: 24129065.
-
Ziv YH, Burrow T, Kocoshis S, Pentiuk S. Encephalopathy in a patient with short bowel syndrome: case report and discussion of the pathophysiology. JPEN J Parenter Enteral Nutr. 2014 May; 38(4):518-20. PMID: 23894171.
-
Burrow TA, Grabowski GA. Velaglucerase alfa in the treatment of Gaucher disease type 1. Clin Investig (Lond). 2011 Feb; 1(2):285-293. PMID: 21927713.
-
Li SC, Chen CM, Goldstein JL, Wu JY, Lemyre E, Burrow TA, Kang PB, Chen YT, Bali DS. Glycogen storage disease type IV: novel mutations and molecular characterization of a heterogeneous disorder. J Inherit Metab Dis. 2010 Dec; 33 Suppl 3:S83-90. PMID: 20058079.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2010 | 1 | 2011 | 1 | 2013 | 2 | 2014 | 1 | 2015 | 5 | 2016 | 2 | 2017 | 3 | 2018 | 1 | 2019 | 1 | 2020 | 1 | 2021 | 2 |
To return to the timeline, click here.
|
Burrow's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|